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Abstract 
This dissertation was written as part of the MSc in International Accounting, Auditing & 
Financial Management at the International Hellenic University.  
This dissertation will try to examine the behavior of a biotech firm related to the 
accounting treatment of Research and Development (therefore R&D) expenses for Tax 
Avoidance or Tax Aggressiveness reasons)/ benefits. During this thesis I will try to 
answer to a major hypothesis, are biotech firm using R&D expenses for Tax 
Aggressiveness reasons. The regression model I will use is the OLS Model. 
The dissertation is composed from five (5) major capitals. First Capital is Introduction, 
where I will try to describe the summary of my thesis, the model and data structure, 
literature review. In the second chapter I will focus more on the methodology 
research, by explaining more the basic variables and the construction of the regression 
model. In the next chapter I will try to explain and present the outcomes of the 
methodology research and finally at the last chapter Conclusions I will comment on the 
outcomes and complete the thesis. 
At this point I would like to thank my supervisor Dr Alexandros Sikalidis for his valuable 
help, without which I would not have been able to complete this dissertation. 
Next I would like to thank all my Professors in the MSc, who helped me to gain 
knowledge and the necessary supplies for the after graduating life. 
Last but not least, I want to thank my wife Eleni for being there and offering me the 
best present a human can ever a get, our unborn child. 
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Introduction 
Tax Aggressiveness or Tax Avoidance is a major problem faced by any government and 
society all over the world. According to International Monetary Fund (therefore IMF) 
one of the major problems every national economy is facing is the par economy, which 
hide and laundry money from terrorist action, violence, trafficking etc. But Tax 
aggressiveness is a major problem which someone can easily identify in almost any 
small, big or huge firm all over the world. 
In this study I will try to examine if Biotechnology firms with R&D active departments, 
which invest any amount of cash, either from own capital or from debt or bonds, 
actually invest for R&D purposes or they just invest for accounting reasons. 
Biotechnology sector is the one with highest amount of investment in R&D 
departments, this because the higher spending in the first year of a new project, is 
equal to higher expectations of success of the project meaning maximization of profits 
and market value of the firm. According to DiMasi, Grabowski and Hansen (DiMasi, 
Grabowski, and Hansen 2016) it takes over $850mill to fully develop a product. Taking 
into considerations the studies of Markarian, Nelson and Cazavan (Markarian, Pozza, 
and Prencipe 2008)(Nelson, Elliott, and Tarpley 2003)(Cazavan-Jeny, Jeanjean, and 
Joos 2011), which lead to the conclusion that for earnings management purposes R&D 
investments would be capitalized. A definition, from Chen et al, I took under 
consideration for Tax Aggressiveness in this thesis is “downward management of 
taxable income through tax planning activities”(Chen et al. 2010). It includes the sum 
of meaning someone could give for Tax Aggressiveness and the major goal for at least 
a few Chief Executive Officer (CEO) or Chief Financial Officer (CFO), (Halioui, Neifar, 
and Abdelaziz 2016) as Halioui, Neifar and Abdeladiz stated. 
It is know that for a company to be sustainable it should also be innovative and for a 
company to be innovative, big if not huge amount of funding should be driven to R&D 
departments. Taking that in consideration I will try to investigate if R&D expenses are 
correlated/ related with Tax Aggressiveness. 
With all the above being said the thesis is about R&D expenses and accounting 
treatment. According to Mustafa Ciftci, Nan Zhou (Ciftci and Zhou 2014) disclosing 
R&D expenses in Financial Statements could possibly improve the value relevance. 
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Almost 34.4% of the listed US firms operate a R&D Department (Hernández 2010). 
Because every state has an obligation to retrieve money lost from Tax Aggressiveness 
or “accidentally” wrong Tax Planning, the US has imposed a corporate Tax of 21% flat 
since 01.01.2018 (Wikipedia). However every State has the right to form the Tax Rate 
on will. In this study I tried to focus on the biotech industry. It inccludes all the USA 
publicly listed Biotechnology firms with tf ICB Industry 4000, tf ICB Subsector 4573, 
Current Currency USD and Primary SIC Code 1311, 2111, 2384, 2833, 2834, 2835, 2836, 
2873, 2911, 3826, 3841, 3845, 4522, 4731, 6726, 6794, 7372, 7374, 7375, 7389, 7812, 
8069, 8071, 8093, 8731 and 8732. Data has been collected for Fiscal Years  2017-2018 
and 2018-2019. Sample apparts from 378 firms. All the for mentioned are a hypo 
industry of the Health Care Industry from the publicly listed companies in the USA.  
The outcomes I expect to have from the thesis and the research will improve the field 
of the existing evidence for this particular topic and will add the delivered results to 
the already existing ones. Furthermore, with the financial crisis we are all preparing to 
get in, because of the effects of Covid-19 as Kilpatrick from Deloitte stated (Kilpatrick 
2020), I hope that the results will contribute to the minimum for economic wellness 
overcome purposes. 
Last, the construction of the thesis is as follows, introduction is the first chapter, 
literature review and hypothesis development construct the second chapter, in the 
third chapter included the empirical analysis and the outcomes and lastly the 
conclusions. 
 
 
 
 
 
 
  -3- 
Literature Review & Hypothesis Development 
Chapter Literature Review & Hypothesis Development I exhibit the scientific outcomes 
from published paper and other internet sources which either agree and support the 
main hypothesis or disagree with it. Furthermore, I present the construction of the 
regression model and the connection I made between Tax Aggressiveness and R&D 
Expenses. 
Tax Aggressiveness 
“Downward management of taxable income through tax planning activities” (Chen et 
al. 2010), as I mentioned already in the abstract part of the thesis, but there are more 
definitions for Tax Aggressiveness from researchers that is why Tax Aggressiveness can 
also be referred as Tax Avoidance or Tax Evasion. One of the crucial factors to measure 
Tax Aggressiveness and more important its parameters is to determine both 
(Shackelford and Shevlin 2001). 
One of the major disadvantages of R&D Investments is the high cash outflows, which 
could create liquidity problems in an unstable environment, for small firms Hao and 
Jaffe 1993;  Mancusi and Vezulli 2010 (Hao and Jaffe 1993) (Mancusi and Vezzulli 
2010). 
 
R&D Investment 
Taking in consideration Jin et al in the year 2018 and other related researchers (Jin, 
Shang, and Xu 2018)(Lev and Sougiannis 1996)(Reynard 1979)(Xu and Sim 2018), who 
said that there is a positive correlation between R&D and the economical performance 
a company has in markets which emerge. Studies has shown that earnings increase is 
associate with R&D Investing, as (Lev and Sougiannis 1996) stated. Forty five years 
earlier (Reynard 1979) researched and actually proved that there is a correlation 
between cutting down R&D Investments and lower earnings. As a result someone 
could easily be lead to the thought that a firm with low liquidity and R&D Investments 
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could apply Tax Avoidance/Aggressiveness. Tax Aggressiveness could be driven either 
from Top Management Executives for self-interest reasons or from liquidity problems. 
Hypothesis Development 
Hypothesis 1 
The most significant elements for detecting Tax Aggressiveness are profitability, debt 
ratios, firm size, Big4 auditor, ROA and Market Book Value. All these financial elements 
have been tested from various other studies from various researchers and have 
already proved the correlation between R&D Investments and Tax Aggressiveness. As 
Clive S Lennox, Wanfu Li, Bin Lin & Zi-Tian Wang (Lennox et al. 2015) said it is more 
usable to find firms with low R&D Investments avoid Tax and to be more Tax 
Aggressive than firms with high R&D Investments. In the late 90s Aboody and Lev 
(Aboody and Lev 1998), proved a positive correlation between R&D capitalization and 
profitability and firm size, for software capitalization of course, but it is also an 
Intangible Asset just as R&D Investments. Almost twenty years after, in August 2008 a 
study (Oswald 2008), Dennis R. Oswald, whose research came in contrast with 
research made in the USA and proved at least for the UK firms that firms in steady-
state has to expect only low gains when talking about worth associates when try to 
modify the book value of equity and already reported earnings for capitalized digits. All 
these in a state where R&D Expenditures and equal to the depreciation. Oliveira, 
Magnani, Tortoli, Figari, Ambrozini 2019 (Oliveira et al. 2019), proved that R&D 
expenses are Investment with long time payback, which means that for the executives 
it is not always easy to decide whether to see them as Intangibles Assets and conclude 
them in the Financial Statements or to treat them as R&D Expenses and capitalize 
them. One more study from Xuemeng Guo, Zhuojun Wang, Chang Liu (Liu, Guo, and 
Wang 2019) took under investigation the firms performance and the R&D intensity, so 
they proved that firms with high R&D expenses have higher Operating Income, which 
gives a whole new look to the side I am trying to see and investigate the hole subject. 
Furthermore (Yüksel 2017) conclude that there is not relationship among Research and 
Development and Financial Growth. According to Doukas and Switzer (Doukas and 
Switzer 1992) with the Study The Stock Market’s Valuation of R&D Spending and 
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Market Concentration 1992, proved that 1 unit of money spent as R&D Investment has 
actually more value if spent by a big firm, than if it was spent by a smaller firm   In this 
study I will try to connect R&D Investments with Tax Aggressiveness for Biotechnology 
Firms. As Namryoung Lee proved in 2018 (Lee 2018), it is more likely for biotechnology 
firms to expect more profits from the success of the development and commercial 
gains anew product could create  than to actually waist it and capitalize it before its 
finished for liquidity or other reasons. In the same research it is also proven that the 
for mentioned behavior is only me in biotechnology industry sector, thus could drive 
us to the guesstimate that a biotechnology firm act like that, because of the passion 
the researchers have and future opportunities. From all the above I make the following 
hypothesis, 
 
Hypothesis1: R&D Investments are negatively correlated with Tax Aggressiveness in 
Biotechnology Industry Sector. 
 
Hypothesis 2 
As usual in life, the same here there is the contrast opinion which implies that there is 
no negative correlation between R&D Investments and Tax Aggressiveness, meaning 
that a firm will strategically use R&D Expenses for Tax Avoidance reasons, because 
R&D Expenditures are Tax deductable as (Stickney and McGee 1982) said. Taking in 
consideration new factor the Cash Effective Tax Rates CETR (Gupta and Newberry 
1997) appointed a non positive relationship with R&D expenses. One more factor is 
the Effective Tax Rate, which react in negative with R&D Intensity, which is calculated 
by dividing Sales to R&D Expenditures, as (Richardson and Lanis 2007) proved. 
According to one of the conclusions that (Hall et al. 2016) from a research contacted 
for the hole of the European Union, state that there are some cases where firm uses 
the R&D tax credits in order to speed Research instead of equal moving Research and 
Development, implicating that there is a way for some firms to benefit from Tax 
Aggressiveness by implying R&D Investments. Last but not least, the study (Huang, 
Krull, and Ziedonis 2020), showed that firms with multinational R&D Expenses have a 
significant degree of implying Tax Aggressiveness, while companies could reach higher 
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levels of tax efficiency Research and Development Invests when decreasing un-tax 
frictions pocked from non strong intellectual ownership secured nad when non 
decreasing the tax utilities earned from foreign Research and Development. 
For the Hypothesis 2 and taking in consideration all the above. I will basically reverse 
Hypothesis 1 and presented as follows, 
 
Hypothesis2: R&D Investments are positively correlated with Tax Aggressiveness in 
Biotechnology Industry Sector. 
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Research Design 
The Chapter Research Design will actually analyze the methodology, which will be used 
to try proving either one of the two Hypotheses, it will also explain the reason why the 
variables depended and not have been chosen and the explanation of them. 
Sample 
To run the proccess of trying to prove either one of the two Hypothesis i have create a 
sample, sample have been collected from ThomsonOne database, provided by the VPN 
from the International Hellenic University. It inccludes all the USA publicly listed 
Biotechnology firms with tf ICB Industry 4000, tf ICB Subsector 4573, Current Currency 
USD and Primary SIC Code 1311, 2111, 2384, 2833, 2834, 2835, 2836, 2873, 2911, 
3826, 3841, 3845, 4522, 4731, 6726, 6794, 7372, 7374, 7375, 7389, 7812, 8069, 8071, 
8093, 8731 and 8732. Data has been collected for Fiscal Years  2017-2018 and 2018-
2019. Sample apparts from 378 firms. Data have been also collected from Annual 
Report Statements from firms sites. Data includes Key Ratios like ROA, ROE, quick 
Ratio, I have also collected Data Market Book Value, Number of Preffered Stocks, 
Leverage Size of the firms, Big4 Audit, R&D department existence and R&D to Sales , 
Sales. International Accounting Standards 
(Olinda, Dossani, and Mcgeachin 2015) sets the accounting treatment of all taxable 
profits and losses, both national and foreign. 
Model Summary
b
 
Model R 
R 
Square 
Adjusted 
R 
Square 
Std. Error of 
the Estimate 
Change Statistics 
Durbin-
Watson R Square 
Change 
F 
Change 
df1 df2 
Sig. F 
Change 
1 .152
a
 ,023 -,029 ,238742006486 ,023 ,440 6 112 ,851 2,416 
a. Predictors: (Constant), ws.Research And Development Expense, MkTBK, tf.Return On Assets, BiG4ad_Slope, 
Lev, SiZe 
b. Dependent Variable: TAXAgg_ETR 
 
Tax Aggressiveness/ Dependent Variable
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Above the table showing the R, R Square and Adjusted R Square for Model 1, also the 
Standard Error of the Estimates, the R Square Change, the F Change, df1, df2 
Significant F Change and the Durbin-Watson. We can also see that the Predictors the 
constant variables are the Research and Development Expenses, the Market to Book 
Value, the ROA, BIG4 Slope, Leverage and the Size of the company. Size of the 
company has been calculated as the deviation results from the Max Total Assets to the 
individual Total Assets of each  firm. 
BIG4 slope is a dummy variable which takes the price of 1 or 0 depdnding in the fact, if 
a firm is being audited from on of the BIG4 Auditing Firms. 
Leverage is calculated as explained later likewise the Market to Book Value. 
Tax Aggressiveness (TAXAgg) is the field of the Degree of Tax Aggressiveness exciding 
the boundaries of legal Tax Planning and overcoming the higher limis of Abusive Tax 
Planning. Actually entering the ilegal and Noncompliance  ground of Tax 
Aggressiveness of commiting Fraud. Tax Aggressiveness.  
From my research in the universe of scientific research bibliografy I have discovered 
that most of the researcers use the Effective Tax Rate ETR combined with the Book Tax 
Gap BTG as proxies to measure Tax Aggressiveness or Avoidnce. I will base my research 
on the published study of David A. Guenther published in August 2014 (Guenther 
2018) who proved that someone can measure Tax Aggressiveness just by using ETR, 
while using BTD can consult with error measurement. 
ETR can be easier truck down through databases and a better explanation can be 
provided from the IAS 12 (Olinda, Dossani, and Mcgeachin 2015) International 
Accounting Standard as formention. I will calculate ETR as the quotient of Total Tax 
Expenses (TTE) by the pre-Tax Income (pTIN)  
ETR=TTE/pTI (Chen et al. 2010).  
Independent Variables R&D_Inv 
For the independent varible i have minned data from the database for R&D/Sales and 
multiply it with the ammount of Sales, so i can calculate the amount a firm spends for 
R&D Department. R&DtoSALES has also limitate the sample from 387 firms to 119 
because not every firm of the starting Sample has an ongoing R&D Department. 
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Control Variables 
For the Control Variables i have used priop research studies and based on their model i 
have collect the following Variable, which are ROA, Lev, MkTBk, SALES, PREFFERED 
STOCKS, BIG4AUD, SIZE Roman Lanis, Grant Richardson, Grantley Taylor (Lanis, 
Richardson, and Taylor 2017). Following i will explain why and how will I use those 
Varibles. 
 
ROA 
Return on Assets is a profitability Ratio measure which measures how profitable a firm 
is regarding its Assets. It is best to use when sample apart from same Industry firms.  In 
this Research it has been retrieved from ThomsonOne DataBase. The formula to 
calculate ROA is dividing Net Income by Total Assets.ROA inform us for the efficiency 
any firm has related to its Assets and the ability to generate Profits from them. ROA 
should be used to compare firm of the same Industry, because of the different 
necessary conditions each kind of Industry works. For example as Service firm which 
sells Insurances does not need a high amount of Assets comparing to a Manufacturing 
Firm, for which High amount of Tangible Assets like, PPE and Raw Material are 
necessary to operate. 
Leverage 
Leverage is calculated by dividing Total Company Debt to Shareholder’s Equity. Data 
have been retrived from Database ThomsonOne, seperately Long Term Debts and 
Total Assets. Leverage is used to specify the amount of debt that is financing the 
operations a firm operates. I have retrieved Total Assets and Total Liabilities and I will 
calculate it all in excel with a formula. Leverage Finance data have been retrieved also 
from ThomsonOne Database. 
MkTBk 
Market Book Value is calculated by dividing The market Value of Equity by the Book 
value of Equity. To calculate the Book-Value of a firm i will divide Assets by T.Liabilities 
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and for the Market-Value i will multiply Stock-Price with Number of Shares, all those 
data have been collectes from ThomsonOne Database. I will use this ratio to see if a 
firm under research is over or under-valued. The formula to calculate 
MarketBook=MarketCapitalization/NetBookValue, where NetBookValue=TotalAssets-
TotalLiabilities. 
BiG4ad 
BiG4ad_Slope 
  Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid 0 30 24,2 24,2 24,2 
1 94 75,8 75,8 100,0 
Total 124 100,0 100,0   
 
 
Big 4 Audited is a dummy variable, which will be taking the prices of 1 if the firms are 
audited from one of the Big4 Auditing Companies (Deloitte, Ernst & Young, KPMG and 
PriceWaterCoopers) or the price 0 if the firm is audited from a different company. As 
seen in the table above a 75,8% (94 firms) of the firms, which appart the sample are 
being audited from either one of one of the Big4 Auditing Firms. On the other hand a 
percentage of 24,2% something less than the one third, is being audited from a non 
Big4 Auditing Firm.  Data has also been retrived from TomsonOne Database and in a 
few cases from the Consolidated Balance Sheets and the Financial Statements the 
firms have posted on the web. 
SiZe 
Size i will calculate it as the divided outcome by dividing Total Assets from each firm by 
max Total Assets Of a Firm. I will run the regression forst in an excel spreadshet and 
the outcomes calculated in a new row will be used for the SPSS to run the regression 
model at the end. Size variable is used to check the proportion every firm stakes in 
comparison to the bigest firm of the sample. Data has also been collected from 
ThomsonOne Database and Compustat. 
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Regression Model 
In order to examine if either one of my two Hypothesis are right or wrong i have to 
construct the regression mode. With the model i will try to check the Tax 
Aggressiveness of R&D Investments in Biotechnology Subindustry firms using the 
independed variables and the control variables, which as mentioned already are the 
R&D Expenses, ROA, Leverage, Market to Book Value, BIG4 Slope and Size respectively: 
 
TAXAggi,t=ao + β1*ROAi,t + β2*Levi,t + β3*MkTBki,t + β4*BiG4adi,t +β5*SiZei,t + 
β6*R&D_Invi,t + εi,t 
 
The indicators i and t define the firm and Fiscal Year respectively, while the α is the 
constant term. The ε is the error term and β1,2,3,4,5,6,7 are slopes. In addition for the 
model TAXAggi,t  Tax Aggressiveness is measured related to ETR.  
To run the model I used Panel Data which were imported from an Excel file to SPSS. 
The method I used is the Ordinary Least Square OLS, which functions under the 
principle of least square, meaning minimization of the summary resulting the square of 
the differences among the noticeable depended variable from the data sample we use 
regarding the projected outcomes from the linear friction. I hope the outcome will 
provide the expected outcomes. 
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Empirical Analysis 
Empirical Analysis is the fourth out of the five chapter this thesis have. In this chapter i 
will present and explain the results and outcomes. Tables including the results and 
outcomes, the autocorrelation matrix and statistic evidences will be presented. When 
trying to put into words the results or outcomes from the statistical anaysis throught 
SPSS of the Regression Model I have constructed. I must first review all the dependent 
and independent variables. Tax Agressiveness is figured as TAXAgg_ETR. The first table 
show us the Variables Entered/Removed for the regression to run, and explains that a. 
Dependent Variable is the Tax Aggressiveness and that b. All requested variables 
entered. 
Variables Entered/Removed
a
 
Model Variables Entered 
Variables 
Removed 
Method 
1 
ws.Research And Development 
Expense, MkTBK, tf.Return On 
Assets, BiG4ad_Slope, Lev, SiZe
b
 
 
Enter 
a. Dependent Variable: TAXAgg_ETR 
b. All requested variables entered. 
 
Empirical Analysis 
 
Notes 
Output Created 10-APR-2020 23:43:48 
Comments   
Input Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data File 124 
Missing Value 
Handling 
Definition of Missing User-defined missing values are treated as 
missing. 
Cases Used Statistics are based on cases with no missing 
values for any variable used. 
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Syntax REGRESSION 
  /DESCRIPTIVES MEAN STDDEV CORR SIG N 
  /MISSING LISTWISE 
  /STATISTICS COEFF OUTS CI(95) R ANOVA 
COLLIN TOL CHANGE 
  /CRITERIA=PIN(.05) POUT(.10) 
  /NOORIGIN 
  /DEPENDENT TAXAgg_ETR 
  /METHOD=ENTER tf.ReturnOnAssets 
BiG4ad_Slope SiZe MkTBK Lev ws.Research And 
Development Expense 
  /SCATTERPLOT=(*ZRESID ,*ZPRED) 
  /RESIDUALS DURBIN HISTOGRAM(ZRESID) 
NORMPROB(ZRESID). 
Resources Processor Time 00:00:01.36 
Elapsed Time 00:00:01.37 
Memory Required 3388 bytes 
Additional Memory Required for 
Residual Plots 
880 bytes 
 
The above table is the first outcome from the SPPSS Database Analytics. After 
importing all the data retrieved from the ThomsonOne Database provided by the VPN 
from the International Hellenic University. I click on Analyze, Regression and then to 
Linear. I set as dependent variable the Tax Aggressiveness and as independent 
variables the Return on Assets, the Big4 Slope, the SIZE, the Market to Book value and 
last the Leverage. In the spreadsheet of SPSS I have imported an excel file with all the 
data, which I retrieved from the database. I have also process some data to calculate 
the slopes and variables like SIZE which is actually the log of the Total Assets. I have 
divide all Total Assets from each company separate to the firms Total Assets with the 
maximum amount (in USD) Total Assets. In the database I have also included some 
more variables which at the end were not necessary for the regression model to run. I 
retrieved them for scientific reason and probably for another Study, which I will 
prepare.  
Descriptive Statistics 
  Mean Std. Deviation N 
TAXAgg_ETR -,06460136854 ,235317174763 119 
tf.Return On Assets -
67,40714285714 
286,505069603867 119 
BiG4ad_Slope ,76 ,431 119 
SiZe ,35 1,806 119 
MkTBK 23,2914701668 196,91893095558 119 
Lev -,13735759245 3,385142315970 119 
ws.Research And 
Development Expense 
170,40 659,298 119 
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In the table above we can see the Mean, the Standard Deviation and the number of 
observations the sample apart from. As seen the mean value for Tax Aggressiveness is 
-0,6460136854, for Return on Assets is -67,40714285714 while for Big4 Slope is 0,76 
for Size is 0,35 and for Market to Book Value is 23,2914701668, on the other hand for 
Leverage is -0,13735759245 and for Research and Development Expenses is 170,50. 
On the third row of the table we see the Std Deviation which takes the prices of 
0,235317174763 for Tax Aggressiveness, 286,505069603867 for ROA, 0,431 for 
BIG4_Slope, 1,806 for SiZe, 196,91893095558 for MkTNK, 3,385142315970 for Lev and 
659,298 for Research And Development Expense. Last but not least the number of 
observation for the sample size is 119. 
From the above table I cannot expect outcomes, which will provide reliable results to 
prove either one of the two for mentioned hypothesis.  
 
Correlations 
  TAXAgg_ETR tf.Return 
On 
Assets 
BiG4ad_Slope SiZe MkTBK Lev ws.Research 
And 
Development 
Expense 
Pearson 
Correlation 
TAXAgg_ETR 1,000 -,098 -,079 -,077 ,027 -,047 -,081 
tf.Return On 
Assets 
-,098 1,000 -,001 ,051 ,008 ,008 ,051 
BiG4ad_Slope -,079 -,001 1,000 ,104 ,042 -,019 ,128 
SiZe -,077 ,051 ,104 1,000 -,014 ,115 ,882 
MkTBK ,027 ,008 ,042 -,014 1,000 ,063 -,017 
Lev -,047 ,008 -,019 ,115 ,063 1,000 ,119 
ws.Research 
And 
Development 
Expense 
-,081 ,051 ,128 ,882 -,017 ,119 1,000 
Sig. (1-
tailed) 
TAXAgg_ETR   ,144 ,197 ,204 ,386 ,307 ,192 
tf.Return On 
Assets 
,144   ,494 ,291 ,466 ,467 ,290 
BiG4ad_Slope ,197 ,494   ,131 ,323 ,420 ,083 
SiZe ,204 ,291 ,131   ,438 ,107 ,000 
MkTBK ,386 ,466 ,323 ,438   ,248 ,427 
Lev ,307 ,467 ,420 ,107 ,248   ,098 
ws.Research 
And 
Development 
Expense 
,192 ,290 ,083 ,000 ,427 ,098   
N TAXAgg_ETR 119 119 119 119 119 119 119 
tf.Return On 
Assets 
119 119 119 119 119 119 119 
BiG4ad_Slope 119 119 119 119 119 119 119 
SiZe 119 119 119 119 119 119 119 
MkTBK 119 119 119 119 119 119 119 
Lev 119 119 119 119 119 119 119 
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In the correlation matrix we can see the coefficient correlation between two variables; 
it is the Pearson pair wise model. What we can actually see is how significant is one 
variable in comparison to another, that’s why when comparing the same variable the 
result is always 1.SiZe to SiZe 1, Lev to Lev 1, BiG4ad_Slope to BiG4ad_Slope 1, Tax 
Aggressiveness to Tax Aggressiveness 1, ROA to ROA 1, R&D Expenses to R&D 
Expenses 1. The total number of the firm under investigation is equal to 119. What I 
can see from the correlation matrix above is that there is a correlation significance 
between SiZe and Research And Development Expense, which is lower than the 0,01 
actually is less than that and equal or less 0,000. The rest of the variables are not 
significant because none is lower that either 0,05 or 0,01. I can also see in the Pearson 
pair wise correlation that the variables Big4_Slope and ROA are correlated, as is ROA 
with Market to Book Value and Leverage. There is also a noticeable significance among 
Big4_Slope and ROA and Market to Book Value, this can be explained from the matrix. 
So SPSS has actually run all the variables to each other and justified the correlation 
among them all. 
 
Coefficients
a
 
Model Unstandardized Coefficients Standardized 
Coefficients 
t Sig. 95.0% Confidence 
Interval for B 
Collinearity Statistics 
B Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
Tolerance VIF 
1 (Constant) -,037 ,045   -,834 ,406 -,126 ,051     
tf.Return On 
Assets 
-7,812E-05 ,000 -,095 -1,017 ,311 ,000 ,000 ,997 1,003 
BiG4ad_Slope -,040 ,051 -,074 -,780 ,437 -,142 ,062 ,980 1,021 
SiZe -,003 ,026 -,023 -,117 ,907 -,054 ,048 ,222 4,503 
MkTBK 3,864E-05 ,000 ,032 ,345 ,731 ,000 ,000 ,993 1,007 
Lev -,003 ,007 -,042 -,444 ,658 -,016 ,010 ,980 1,021 
ws.Research 
And 
Development 
Expense 
-1,444E-05 ,000 -,040 -,203 ,839 ,000 ,000 ,220 4,537 
 
From the table above I can see that there is a statistical significance. I mean that my 
hypothesis according to the test is in the accepted areas, from the probability of 
ws.Research 
And 
Development 
Expense 
119 119 119 119 119 119 119 
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default tables I see that that my rejects region is from the values of -2,29 and 2,29. So 
all the results for the t which are -0,834 -1,017 -0,78 -0,117 0,345 -0,444 and -0,203 are 
in the accepted area or in the 95% of the accepted region. So I can accept my 
hypothesis that R&D Expenses/Investments are related with Tax Aggressiveness, BUT 
this is not the case for Biotechnology Companies. The reason why this is happening is 
unexplained from this thesis, but it could be an interesting field of research. According 
to the literature and guesses it could be because of the potential profits a firm 
biotechnology firm could have from the competences of a project. We can also notice 
that there is not a single one variable with a higher than 10 value at the Statistics VIF, 
which means that there is not a problem with the model. In the next step I will see at 
the Collinearity Diagnostics where in the Variance Proportions there is one problem 
with collinearity at the Leverage with price 0,92 and 0,91, which determines that there 
is a problem with the variable. 
 
Collinearity Diagnostics
a
 
Model Eigenval
ue 
Condition 
Index 
Variance Proportions 
(Constant) tf.Return 
On 
Assets 
BiG4ad_Slope SiZe MkTBK Lev ws.Research 
And 
Development 
Expense 
1 1 2,398 1,000 ,03 ,01 ,03 ,02 ,00 ,00 ,02 
2 1,548 1,245 ,03 ,07 ,02 ,04 ,01 ,04 ,03 
3 1,042 1,517 ,00 ,00 ,00 ,00 ,52 ,40 ,00 
4 ,934 1,602 ,00 ,49 ,00 ,00 ,20 ,32 ,00 
5 ,836 1,693 ,02 ,42 ,02 ,01 ,26 ,24 ,01 
6 ,130 4,302 ,92 ,00 ,91 ,01 ,00 ,00 ,01 
7 ,112 4,635 ,00 ,00 ,02 ,93 ,00 ,00 ,94 
 
In the table above where the values in the second row 1-7 are, are the variables Tax 
Aggressiveness, ROA, Big4_Slope, SiZe, MkTBK, Lev and Research and Development 
Expenses respectively. In the Collinearity Diagnostics I check for prices over 0,9 there 
are two for Leverage. First one Leverage to Tax Aggressiveness and second one 
Leverage to BIG4_Slope. There is also one price over 0,9 R&D Expense to R&D Expense. 
 
Residuals Statistics
a
 
  Minimum Maximum Mean Std. Deviation N 
Predicted 
Value 
-,19664780796 ,16389244795 -,06460136854 ,035701786158 119 
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Residual -
1,711532711983 
,575333952904 ,000000000000 ,232593110826 119 
Std. 
Predicted 
Value 
-3,699 6,400 ,000 1,000 119 
Std. 
Residual 
-7,169 2,410 ,000 ,974 119 
a. Dependent Variable: TAXAgg_ETR 
 
In the Residuals Statistics table I can see that the residual has a mean of 0 so we don’t 
have to check it, the same goes for Std Predicted Value and for Std Residual. 
 
 
 
ANOVA
a
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression ,150 6 ,025 ,440 .851
b
 
Residual 6,384 112 ,057     
Total 6,534 118       
a. Dependent Variable: TAXAgg_ETR 
b. Predictors: (Constant), ws.Research And Development Expense, MkTBK, tf.Return On 
Assets, BiG4ad_Slope, Lev, SiZe 
  
In the ANOVA table we see that the significance is not even close statistical significance 
because it is not close to 0, but 0,851 the sample is homogenous. The higher the F 
score gets the lower the Significance will get. So almost 85,1% is the percentage that 
the hypothesis will happen. 
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Outcomes 
From the empirical analysis and the run of the regression model, which was made in 
the SPSS program, I can see that there is a significance correlation. Meaning that the 
hypothesis 1 is accurate. So I can say that, R&D Investments are negatively correlated 
with Tax Aggressiveness in Biotechnology Industry Sector. In the Biotechnology 
Industry there is a negative correlation among R&D Investments and Tax 
Aggressiveness. This is happening because there is almost always a positive correlation 
between the expected outcomes of a product or a service which is still tested and 
researched (still in the R&D Department and no yet offered in the market), than the 
capitalization of a service or product before it is ready to be offered o the public for 
sale (Lee 2018). I think, that in Biotechnology Industry it would also be more 
detrimental for a company to either capitalize an R&D Project before it is ready for to 
be offered or to avoid taxes.  
The first case, where an R&D Project is capitalized or canceled before it is complete, it 
would mean, that the firm is facing financial problems or that there is a shift of acts or 
plans, which could possibly have negative outcomes for the firm’s financial 
performance and the way the stockholders and shareholders see the firm’s future. On 
the other hand the scenario where R&D Investments are being made for Tax 
Avoidance reasons could have massive outcomes for a Biotechnology firm prestige.  
When taking in consideration the research of Lee 2018 (Lee 2018) “ R&D Accounting 
Treatment, R&D State and Tax Avoidance: With a Focus on Biotech Firms”, who proved 
that Tax Avoidance and R&D Investments are not correlated meaning that when Tax 
Avoidance occurs, this is not the case for R&D Investments. As Dennis R. Oswald, in 
August 2008 said (Oswald 2008), whose research came in contrast with research made 
in the USA and proved at least for the UK firms that firms in steady-state has to expect 
only low gains when talking about worth associates when try to modify the book value 
of equity and already reported earnings for capitalized digits. As Oliveira and et al in 
2019 (Oliveira et al. 2019) proved that R&D expenses are Investment with long time 
payback, which means that for the executives it is not always easy to decide whether 
to see them as Intangibles Assets and conclude them in the Financial Statements or to 
treat them as R&D Expenses and capitalize them. As Yüksel in 2017  (Yüksel 2017) 
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conclude that there is not relationship among Research and Development and 
Financial Growth. So, when parallelize the results of my research model and all the for 
mentioned researchers conclusions, but with a major respect to Lee 2018 I could come 
to the conclusion that my Hypothesis 1 is true and accepted. 
Meaning that there is not a positive correlation between the R&D Investments and Tax 
Aggressiveness, for Biotechnology Industry in the USA publicly listed firms in the 
NASDAG. 
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Conclusions 
Concluding the Thesis “R&D Investments and Tax Aggressiveness with a focus on 
Biotechnology Firms”. In the first chapter “Introduction” I explain the general 
fundamentals, which will follow. An explanation for Tax Aggressiveness is presented 
from Chen et al. and then a small summary of the sample like the Industry, Country, 
Sub Sector, SIC etc are given. In the second chapter “Literature Review & Hypothesis 
Development”, an explanation of the terms Tax Aggressiveness and R&D Investments 
are being made. A historical review of case studies and published paper are being 
exhibited to either support the Hypothesis1 “R&D Investments are negatively 
correlated with Tax Aggressiveness in Biotechnology Industry Sector”; and a same 
historical review follows to either vote against the first Hypothesis or, if can say, or to 
support the Hypothesis 2 “R&D Investments are positively correlated with Tax 
Aggressiveness in Biotechnology Industry Sector”. Almost 22 case studies apart the 
chapter 2. 
In chapter 3 “Research Design” it concludes by the sample and the dependent and 
independent variables. Samples inccludes all the USA publicly listed Biotechnology 
firms with tf ICB Industry 4000, tf ICB Subsector 4573, Current Currency USD and 
Primary SIC Code 1311, 2111, 2384, 2833, 2834, 2835, 2836, 2873, 2911, 3826, 3841, 
3845, 4522, 4731, 6726, 6794, 7372, 7374, 7375, 7389, 7812, 8069, 8071, 8093, 8731 
and 8732. Data has been collected for Fiscal Years  2017-2018 and 2018-2019. Sample 
apparts from 124 firms. Data have been also collected from Annual Report Statements 
from firms sites. Data includes Key Ratios like ROA, ROE, quick Ratio, I have also 
collected Data Market Book Value, Number of Preffered Stocks, Leverage Size of the 
firms, Big4 Audit, R&D department existence and R&D to Sales , Sales. International 
Accounting Standards. Tax Aggressiveness is the dependent variable of the regression 
model and R&D Investments is the indipendent variable. For calculating Tax 
Aggressiveness the Effective Tax Rate is computed andcalculated as he percentage of 
the Taxable Income divided by the Income Payable Taxes. To calculate R&D 
Investments because in the beginning of the research it was not clear from the 
databases and the Internet sites of the firms under investigations, if there was an 
active R&D Department. Data for R&D Sales, R&D Expenses, Sales to R&D were 
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collected, by the end of the day throught Compustat R&D Investments were mined 
and used to run the regression model. As control variables i used the ratios and logs 
Return On Assets, Size of the Firm, Market to Book Value, Big4 Slope and Leverage. All 
data were collected from ThomsonOne database with access given throught the VPN 
of the International Hellenic University. Variables like Big4 are Dummy Variable, which 
took prices of 1 if firms where audited by one of the Big 4 Auditing Firms (Delloite, 
PWC, KPMG, EY); and the price of 0 if any other Auditing Firm where to audit the firms 
under investigation. Variables like Size is the result of the deviation of Total Assets of a 
form devided by the Total Asset of the Firm with the Maximum Ammount of Total 
Assets. Leverage variable is also mine throught the database ThomsonOne and in a few 
cases from the online posted Financial Statements from the firm websites. Market to 
Book Value was calculated as the Market Capitalization devide by Net Book Value, 
where Market Capitalization is the Number of Stocks multiplied with the Current Stock 
Price; and Net Book Value is the result of Total Assets minus Total Liabilities, data 
where also retrieved from ThomsonOne database. Last but not least, the Regression 
Model was build, set and ready to run in the SPSS. 
In the next Chapter “Empirical Analysis”, the outcomes of the SPSS are presented. The 
tables of Variables Entered/Removed, Notes, Correlation, Coefficients, Collinearity 
Descriptive Statistics, Residual Descriptives, Collinearity Diagnostics and ANOVA are 
content and explained in the Chapter. From the for mentioned tables the Hypothesis 1 
“R&D Investments are negatively correlated with Tax Aggressiveness in Biotechnology 
Industry Sector”, is slightly moving to the accepted area.  As outcomes and conclusions 
after running the regression model and finishing the research, I can say that it is not 
accepted to say that there is a relationship, of any kind, between R&D Investments and 
Tax Aggressiveness, in the Biotechnology Industry for the publicly listed  Biotechnology 
firms in the NASDAG. The hypothesis 1 “R&D Investments are negatively correlated 
with Tax Aggressiveness in Biotechnology Industry Sector”.  
Last but not least, and after completing this research some new and very interesting 
fields to research come to my notice. A few of them are the Tax Aggressiveness and 
R&D Investments in democratic (west) countries in contrast to the Tax Aggressiveness 
and R&D Investments in a non-democratic (east) country. One more really interesting 
topic about Tax Aggressiveness is the par economy, and how in some cases it is 
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practically allowed by the auditing committees of some countries. Finally, I would like 
to try research the effectiveness of the cash being driven to the R&D Departments, and 
the correlation among Tax Return from R&D Investments in countries like Philippines, 
where the Tax Return rate is and used to be much more advantageous, according to EY 
(“Worldwide” 2018). 
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Appendix 
TAXAgg_ETR 
  Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid -1.789473684 1 ,8 ,8 ,8 
-.848766131 1 ,8 ,8 1,6 
-.747018970 1 ,8 ,8 2,4 
-.522256685 1 ,8 ,8 3,2 
-.439065389 1 ,8 ,8 4,0 
-.434782609 1 ,8 ,8 4,8 
-.414783463 1 ,8 ,8 5,6 
-.410429695 1 ,8 ,8 6,5 
-.399792202 1 ,8 ,8 7,3 
-.396957207 1 ,8 ,8 8,1 
-.378378378 1 ,8 ,8 8,9 
-.335025381 1 ,8 ,8 9,7 
-.281690141 1 ,8 ,8 10,5 
-.269470405 1 ,8 ,8 11,3 
-.262864426 1 ,8 ,8 12,1 
-.234834999 1 ,8 ,8 12,9 
-.234741548 1 ,8 ,8 13,7 
-.209960938 1 ,8 ,8 14,5 
-.164194694 1 ,8 ,8 15,3 
-.156385752 1 ,8 ,8 16,1 
-.129725581 1 ,8 ,8 16,9 
-.129253229 1 ,8 ,8 17,7 
-.115384615 1 ,8 ,8 18,5 
-.056084656 1 ,8 ,8 19,4 
-.055335968 1 ,8 ,8 20,2 
-.044665516 1 ,8 ,8 21,0 
-.024635433 1 ,8 ,8 21,8 
-.011843079 1 ,8 ,8 22,6 
-.011815252 1 ,8 ,8 23,4 
-.007657596 1 ,8 ,8 24,2 
-.000827454 1 ,8 ,8 25,0 
-.000801282 1 ,8 ,8 25,8 
-.000241022 1 ,8 ,8 26,6 
-.000168698 1 ,8 ,8 27,4 
.000000000 1 ,8 ,8 28,2 
.000000001 72 58,1 58,1 86,3 
.000164465 1 ,8 ,8 87,1 
   
  -2- 
.000425279 1 ,8 ,8 87,9 
.000468274 1 ,8 ,8 88,7 
.000488162 1 ,8 ,8 89,5 
.002050815 1 ,8 ,8 90,3 
.003323837 1 ,8 ,8 91,1 
.005054354 1 ,8 ,8 91,9 
.006124722 1 ,8 ,8 92,7 
.008294931 1 ,8 ,8 93,5 
.008438819 1 ,8 ,8 94,4 
.015382558 1 ,8 ,8 95,2 
.043623229 1 ,8 ,8 96,0 
.044939429 1 ,8 ,8 96,8 
.068296216 1 ,8 ,8 97,6 
.362626055 1 ,8 ,8 98,4 
.380460037 1 ,8 ,8 99,2 
.544561934 1 ,8 ,8 100,0 
Total 124 100,0 100,0   
 
 
BiG4ad_Slope 
  Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid 0 30 24,2 24,2 24,2 
1 94 75,8 75,8 100,0 
Total 124 100,0 100,0   
 
 
Model Summary
b
 
Mod
el 
R R 
Squa
re 
Adjus
ted R 
Squa
re 
Std. Error of 
the Estimate 
Change Statistics Durbin-
Watson R Square 
Change 
F 
Chan
ge 
df1 df2 Sig. F 
Change 
1 .15
2
a
 
,023 -,029 ,23874200648
6 
,023 ,440 6 112 ,851 2,416 
a. Predictors: (Constant), ws.Research And Development Expense, MkTBK, tf.Return On Assets, 
BiG4ad_Slope, Lev, SiZe 
b. Dependent Variable: TAXAgg_ETR 
 
 
ETR=TTE/pTI (Chen et al. 2010); where, 
ETR: Effective Tax Rate, 
TTE: Total Tax Expenses, and 
pTI: pre-Tax Income 
 
 
   
  -3- 
MarketBook=MarketCapitalization/NetBookValue; where, 
Market Capitalization= Number of Stocks*Current Stock Price (13th April 2020) 
NetBookValue=TotalAssets-TotalLiabilities. 
 
TAXAggi,t=ao + β1*ROAi,t + β2*Levi,t + β3*MkTBki,t + β4*BiG4adi,t +β5*SiZei,t + 
β6*R&D_Invi,t + εi,t :where, 
TAXAgg: Tax Aggressiveness, 
ROA: Return On Assets, 
Lev: Leverage, 
MkTBk: Market to Book Value, 
BiG4ad: Big 4 Auditor, 
SiZe: Size of the firm, and 
R&D_Inv: R&D Investments 
 
